Among patients with NSCLC treated with anti-PD-1 mAb, higher non-synonymous TMB seemed to be related with greater benefit, but a large phase III randomized trial did not confirm these preliminary observations (54). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.